Easton Pharmaceuticals, Inc designs, produces, and sells premium health care products. Most of them use the proprietary transdermal gel formulation that the Canadian company has developed. In 2013, Easton Pharma also announced that it has begun breaking into the medical marijuana sector.
The company was founded in 1997 and originally operated as LAM Pharmaceutical Corp. It became Easton Pharmaceuticals, Inc in 2010.
With a market cap pegged at USD 1.26 M, Easton Pharmaceuticals currently trades in the OTC markets as EAPH.
Products of the company are targeted towards various health issues. Most are applied topically but have transdermal effects due to Easton’s unique proprietary delivery system. There is the arthritis- and body-pain reliever Kenestrin Gel, the anti-wrinkle cream Skin Renou HA, the female sexual enhancement gel Viorra, and the motion sickness reliever gel Nauseasol.
In addition, Easton Pharmaceuticals is working on two major products in its pipeline. These are the early-stage cancer drug called XILIVE and the transdermal treatment for Female Sexual Arousal Disorder (FSAD) called Femlife.
For its entry into the marijuana industry, Easton Pharmaceuticals revealed its intention to establish medical marijuana clinics in Canada and the US. It has also started to discuss investment proposals, such as the one with a Michigan-based medical marijuana dispensary.
The company’s biggest move so far on this front is its investment in AMFIL Technologies. AMFIL is the manufacturer of a plant-growing system called the mPact-GROzone Antimicrobial System, whose technologies reduce pathogens and pests inside cannabis grow facilities.
Easton Pharmaceuticals, Inc is led by CEO and President Carla Pepe, CFO John Adams, COO Kent A Deuters, Treasurer Dr. Peter J. Rothbart, and Chief Marketing and Technology Officer Dr. Lilla Albert. Alongside them is Dr. Daniel Bagi as the Senior Executive Physician Consultant.
Yahoo! Finance: EAPH News
Latest Financial News for EAPH